Medicine :低血清尿酸与卒中后抑郁相关

2015-11-23 MedSci MedSci原创

卒中后抑郁(PSD)是卒中常见的并发症,并与卒中患者不良预后相关。这篇研究旨在探索PSD患者和血清尿酸的相关性。研究者招募了196了急性缺血性患者和100个健康自愿者。应用尿酸酶PAP法检测入院24 小时血清尿酸水平。卒中后3个月评估患者神经心理学。应用17项汉密尔顿抑郁量表评估抑郁症状。PSD的诊断与DSM-IV抑郁诊断标准一致。应用多变量logistic回归模型进行分析。共有56(28.6%)

卒中后抑郁(PSD)是卒中常见的并发症,并与卒中患者不良预后相关。这篇研究旨在探索PSD患者和血清尿酸的相关性。研究者招募了196了急性缺血性患者和100个健康自愿者。

应用尿酸酶PAP法检测入院24 小时血清尿酸水平。卒中后3个月评估患者神经心理学。应用17项汉密尔顿抑郁量表评估抑郁症状。PSD的诊断与DSM-IV抑郁诊断标准一致。应用多变量logistic回归模型进行分析。

共有56(28.6%)名患者三个月时诊断为PSD。与非PSD患者相比,PSD患者基线尿酸水平较低(237.02 ± 43.43 vs 309.10 ± 67.44 μmol/L)。在多变量回归模型分析中,校正可能变量后,尿酸水平(≤239μmol/L和≥328.1 μmol/L)与PSD发生独立相关(OR,7.76;95% CI,2.56-23.47,OR, 0.05;95% CI,0.01-0.43)。

入院血清尿酸水平与PSD相关,并可预测卒中后3个月的进展情况。

原文出处:

Gu Y, Han B, Wang L,et al.Low Serum Levels of Uric Acid are Associated With Development of Poststroke Depression.Medicine (Baltimore). 2015 Nov.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2017-05-30 海棠胜雪

    学习了谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2017-04-07 lemon985

    有意思

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2016-07-27 kalseyzl
  5. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2016-06-13 jeanqiuqiu
  6. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2015-11-24 lovetcm

    研究切入点不错,尿酸越来越受重视

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=204334, encodeId=30c92043341a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCl4zaE0zq0kFsKQmg3vef7gFticiaFX50TWZibZibNHbk3YSJ5uSh1a0DcUiaVIHkoe2Om3eYg7oUTlf/0, createdBy=442c2063958, createdName=海棠胜雪, createdTime=Tue May 30 08:08:59 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185642, encodeId=cc0e185642fb, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Fri Apr 07 00:19:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671215, encodeId=572816e121555, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Apr 04 22:15:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773513, encodeId=3fcc1e73513aa, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jul 27 04:15:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858637, encodeId=6da4185863e3b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Jun 13 00:15:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466349, encodeId=b4f81466349bf, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577443, encodeId=e53215e7443d9, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606725, encodeId=520c1606e2559, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 11:15:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43654, encodeId=5d7043654fb, content=研究切入点不错,尿酸越来越受重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue Nov 24 13:53:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43629, encodeId=feb443629bf, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 06:55:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2015-11-24 owlhealth

    挺好

    0

相关资讯

BMC Musculkel Dis:小心啦!食用西红柿可引起痛风的发作

来自新西兰奥塔哥大学的一项新的研究表明,习惯吃西红柿的人可能会引起痛风的发作,此研究首次发现了二者关联的生物学基础,该研究成果发表于BMC Musculoskeletal Disorders。痛风发作时十分痛苦,为可损害关节功能的炎性疾病,男性发病率较女性高约3倍。新西兰约五分之四的男性患有痛风。对伴有痛风的个体,食用某些食物可能会引起其痛风的发作,奥塔哥生物化学研究人员发现西红柿是引起痛风发作的

Lancet Neurol:尿酸治疗急性期脑卒中无效

尽管发病4.5小时内静脉溶栓治疗可以挽救缺血半暗带的濒死神经元,然而,多数卒中患者仍然残留明显的神经功能障碍。许多脑保护治疗手段不仅能促进卒中慢性期的神经再生,在急性期亦能够通过抗氧化等作用减轻神经元缺血损伤,进而改善患者预后。因此急性期给予静脉溶栓联合脑保护治疗是卒中治疗的理想策略。尿酸是人体重要的内源性抗氧化物质,既往研究发现,卒中患者血清尿酸水平高预示预后以及溶栓治疗疗效较好。但是,卒中后尿

Stroke:女性缺血性卒中联用尿酸治疗效果更佳

 由于高耗氧导致的氧化损伤对于缺血性脑损伤有很大的危害。尿酸是嘌呤代谢的最终产物,是一种潜在的抗氧化物。尿酸的作用包括了清楚羟基自由基、过氧化氢和过氧硝酸盐等。目前,治疗急性缺血性卒中使用抗氧化药物和血栓溶解药物组合的处方,但是男女对这一处方是否有着相同的响应尚未明确。因此,研究人员分析了使用阿替普酶治疗急性缺血性卒中的患者对于尿酸疗法的响应的性别差异。在一项联用尿酸的临床试验中,206

重磅炸弹!FDA委员会通过了用于痛风治疗的新药——lesinurad

FDA委员会通过了用于痛风治疗的新药——lesinurad 近日,FDA委员会以10:4的结果通过了lesinurad(200 mg/d)用于治疗痛风相关的高尿酸血症,可联合黄嘌呤氧化酶抑制剂(XOLs)共同用药。Sean Bohen博士,全球药物开发执行副总裁和首席医疗官,认为委员会推荐lesinurad用于痛风的治疗是个令人激动的进步。他期待这能为痛风的治疗提供一种新的治疗方法:当与黄嘌呤氧化

BMJ:左外踝巨大渗出性包块病例报道

61岁精神分裂症男性,以发烧、疲劳、腿部疼痛和行走困难为主要表现。在他的腿和手肘有质硬包块,最大的位于左外踝(直径14cm),且有开放性创口,持续渗出。X线:病变区域有软组织包块和多个钙化灶。渗出物含有针状晶体,该物质见于痛风石。患者最初的尿酸值为494 µmol/L。患者停止服用治疗高尿酸血症的药物:苯溴马隆和柠檬酸钾;开始口服别嘌呤醇、栓剂双氯芬酸、静注盐酸头孢替安。原始出处:Tomohiko

尿酸转运蛋白的研究进展

尿酸是嘌呤化合物代谢的终末产物,嘌呤代谢紊乱可致尿酸水平升高而产生高尿酸血症。临床研究证实,高尿酸血症与糖尿病、高血压以及高脂血症之间存在着紧密相关性,并可诱发炎性反应,加重血管内皮损伤,最终加速冠心病和肾脏损伤的进展。 现已发现多种转运蛋白参与了肾脏近曲小管对尿酸盐的 转运过程。包括尿酸重吸收蛋白:尿酸盐阴离子转运体1(URAT1),有机阴离子转运体4(0AT4)和葡萄糖转运体9(G